Stephen J Fey

This inventor holds 15 USPTO granted patents and 6 published patent applications and 7 EPO patents. Top assignees: Drugmode Aps, Pride Proteomics A/s, Zadec Aps. Active years: 1999-2026.

USPTO Granted Patents = 15 (Patent Applications = 6)

% Patents Active = 60.0

EPO Patents = 7 (Patent Applications = 10)

Average Co-Inventor Count = 3.1

ph-index = 4

Forward Citations = 66(Granted Patents)

Location History:

Aarhus C, DK (1999 - 2007)
Arhus C, DK (2008)
DK-8000 Aarhus C, DK (2003 - 2009)
Aarhus, DK (2009)
Rhus, DK (2010)
Blommenslyst, DK (2014 - 2019)

Company Filing History:

Universitè Catholique De Louvain

patents

6. 4 out of 834,411

Other

patents

Years Active: 1999-2026

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12655376 - Cell culture chamber device for cell and tissue growth (2026-06-16),

2. 10174065 - Antidiabetic enolic glucoside of phenylpyruvic acid (2019-01-08),

3. 9850458 - Bioreactor with lid for easy access to incubation cavity (2017-12-26),

4. 9574166 - Bioreactor system (2017-02-21),

5. 9221860 - Antidiabetic enolic glucoside of phenylpyruvic acid (2015-12-29),

6. 8877717 - Anti-diabetic extract of rooibos (2014-11-04),

7. 7655471 - Biochemical markers of the human endometrium (2010-02-02),

8. 7531323 - Diabetes-mediating proteins and therapeutic uses thereof (2009-05-12),

9. 7521193 - Human diabetes-mediating proteins (2009-04-21),

10. 7470542 - Proteins in type 2 diabetes (2008-12-30),

11. 7279274 - Method for diagnosing diabetes in a mammal (2007-10-09),

12. 7078375 - Diabetes-mediating proteins and therapeutic uses thereof (2006-07-18),

13. 6640000 - Method and apparatus for analyzing images (2003-10-28),

14. 6611766 - Proteome analysis for characterization of up-and down-regulated proteins in biological samples (2003-08-26),

15. 5939270 - Markers for organ rejection (1999-08-17),

Title: **The Innovative Mind of Stephen J Fey: Contributions to Medicine and Biotech**

Introduction

Stephen J Fey is a distinguished inventor based in Aarhus C, Denmark. With a remarkable portfolio of 14 patents, Fey has made significant contributions to the fields of medicine and biotechnology. His work focuses on creating innovative solutions for prevalent health issues, particularly in the management of diabetes and improving bioreactor technology.

Latest Patents

Among his latest patents, Fey has introduced an antidiabetic enolic glucoside of phenylpyruvic acid. This compound serves as a medicament to help lower blood glucose levels in mammals suffering from obesity, pre-diabetes, or diabetes. The invention aids in managing blood sugar levels by enhancing glucose uptake in cells and normalizing glucose tolerance, thereby improving the overall glycemic response.

Another notable patent is a bioreactor equipped with a lid that grants easy access to its incubation cavity. This innovative design allows for the complete accessibility of the incubation area upon the removal of the cap, facilitating more efficient handling and experimentation.

Career Highlights

Fey's impressive career includes work with various companies, contributing his expertise in both research and practical applications. Notable collaborations with his coworkers, including Peter Mose Larsen and Allan E Karlsen, have further enhanced the quality and reach of his inventive projects.

Collaborations

Collaboration has been a key aspect of Fey's career. Working alongside peers such as Peter Mose Larsen and Allan E Karlsen has likely allowed him to combine their diverse skills and insights, driving forward the innovative processes behind his patents.

Conclusion

Stephen J Fey exemplifies the spirit of innovation through his patents and collaborations. His dedicated efforts to advance medical technologies and improve bioreactor designs have made a lasting impact on the fields of medicine and biotechnology. As he continues to innovate, Fey's work holds the potential to further revolutionize how we manage health and leverage bioprocessing technologies.